Oligonucleotide Synthesis Market Size, Share, and Growth Forecast 2026 - 2033

Oligonucleotide Synthesis Market by Product (Synthesized Oligonucleotides, Reagents, Equipment, Services), Application (Research, Diagnostics, Therapeutics, Drug Discovery, Others), End-User (Pharmaceutical Companies, Biotechnology Companies, Academic and Research Institutes, Diagnostic Laboratories, Others), and Regional Analysis for 2026 - 2033

ID: PMRREP3296
Calendar

November 2026

197 Pages

Author : Pravin Rewale

Oligonucleotide Synthesis Market Size & Trends Analysis

The global oligonucleotide synthesis market is expected to be valued at US$ 5.4 billion in 2026 and is projected to reach US$ 10.0 billion by 2033, growing at a CAGR of 9.2% between 2026 and 2033.

Market growth is driven by the rapid maturation of oligonucleotide therapeutics, which require large volumes of GMP-grade material, alongside steady demand from molecular diagnostics and genomics research. The U.S. Food and Drug Administration (FDA) has approved about 20 antisense, siRNA, and aptamer drugs, beginning with Onpattro in 2018 as the first approved siRNA therapy. Every sequencing panel, PCR assay, and CRISPR experiment also depends on synthetic primers, probes, and guide RNAs. In addition, capacity investments by Danaher Corporation, Agilent Technologies, Inc., Lonza Group AG, and Bachem Holding AG are expanding supply to meet rising demand across clinical and research settings.

Key Industry Highlights

  • Leading Region: North America is expected to lead the oligonucleotide synthesis market with an estimated 37% share in 2026, supported by a dense cluster of drug developers, leading synthesis suppliers, NIH funding, and a clear FDA approval pathway. Domestic GMP capacity expansion further strengthens regional leadership.
  • Fastest-Growing Region: Asia Pacific is the fastest-growing region, registering an estimated 11.0% CAGR from 2026 to 2033, driven by contract manufacturing capacity in China and South Korea, expanding diagnostics, and government support for biotechnology. Local manufacturing improves cost competitiveness for Western sponsors.
  • Dominant Segment: Synthesized oligonucleotides are the dominant product segment, accounting for an estimated 42% market share in 2026, supported by recurring demand across diagnostic, research, and therapeutic applications.
  • Fastest-Growing Segment: Reagents are the fastest-growing product segment, growing at an estimated CAGR of 10.6% through 2033, driven by increasing synthesis volumes and rising demand for high-quality raw materials.
  • Key Market Opportunity: Therapeutic pipeline expansion, outsourcing, and greener chemistries create an incremental opportunity of US$ 4.6 billion for reagent suppliers and contract manufacturers through 2033. Outsourcing partnerships further support revenue growth.

oligonucleotide-synthesis-market-size-2026-2033

See exactly what you're buying — Before you spend a dollar.

Get a free sample copy of our market report: data, tables, charts, research depth, analyst insights, and relevance of our research - all in hand before you commit.

Market Dynamics

Drivers - Expanding Pipeline and Approvals of Oligonucleotide Therapeutics

Oligonucleotide therapeutics have moved from niche rare-disease products to mainstream medicines, and each approval increases demand for synthesis capacity. The FDA has approved about 20 oligonucleotide drugs, including Spinraza in 2016, Onpattro in 2018, Leqvio in 2021, Tryngolza in December 2024, and Qfitlia in March 2025. Alnylam Pharmaceuticals reported net product revenues above US$ 1.5 billion in 2024, demonstrating the commercial potential of these therapies, while Ionis Pharmaceuticals continues to advance a broad antisense pipeline.

Because chronic therapies such as Leqvio, a twice-yearly cholesterol injection, require manufacturing at multi-kilogram scale, sponsors are signing long-term supply agreements with producers including Agilent Technologies, Inc., Bachem Holding AG, Nitto Avecia, Inc., and ST Pharm Co., Ltd. This visible commercial success is attracting further investment in new sequences and chemistries.

Growth of Molecular Diagnostics, Genomics, and Gene-Editing Research

Diagnostics and research workflows consume large volumes of short synthetic oligonucleotides as primers, probes, adapters, and guide RNAs. The World Health Organization (WHO) reported more than 770 million confirmed COVID-19 cases, and the testing response, built on RT-PCR primers and probes, expanded global capacity at suppliers such as Integrated DNA Technologies, LGC Biosearch Technologies, and Eurofins Scientific SE. Genomic medicine adds further demand: Genomics England completed sequencing of 100,000 genomes, and UK Biobank holds data on about 500,000 participants.

Gene editing has also reached the clinic, with the FDA approving Casgevy, the first CRISPR-based therapy, in December 2023, which relies on synthetic guide RNA. Funding from the National Institutes of Health (NIH), which invests roughly US$ 47 billion annually, supports routine purchases of custom oligonucleotides by academic laboratories.

Restraints - High Environmental Footprint and Process Inefficiency of Solid-Phase Synthesis

Most commercial oligonucleotides are manufactured using solid-phase phosphoramidite chemistry, which consumes large volumes of solvents and reagents. A 2021 analysis by the American Chemical Society Green Chemistry Institute Pharmaceutical Roundtable, published in the Journal of Organic Chemistry, found an average process mass intensity of about 4,300 kg of material per kilogram of oligonucleotide, far above that of typical small-molecule processes. Acetonitrile is the dominant solvent, and waste handling increases both production costs and environmental scrutiny.

Yield is also constrained by chemistry: at 99% coupling efficiency, a 50-mer yields only about 61% full-length product, making purification intensive. These inefficiencies increase the cost of goods, especially for high-dose or long-sequence products, and lead some developers to restrict programs to indications that justify premium pricing, thereby restraining broader adoption.

Delivery Limitations, High Therapy Costs, and Capacity Constraints

Most approved siRNA drugs rely on GalNAc conjugation to reach the liver, while delivery to muscle, brain, lung, and other tissues remains difficult, narrowing the addressable disease space. Therapy prices are also high, as Spinraza carried a list price of about US$ 750,000 in the first year of treatment in the United States, creating payer resistance and limiting reimbursement for large populations. Capacity is another constraint. Therapeutic-grade production requires specialized synthesizers, high-pressure chromatography, and rigorous impurity control, and only a limited number of contract manufacturers can deliver at commercial scale.

Long lead times for phosphoramidites, specialty solid supports, and equipment can delay clinical supply, while any quality failure can halt a trial. Together, these barriers slow pipeline progression and limit how quickly synthesis demand translates into production volumes.

Opportunities - Reagents, Green Chemistry, and Raw-Material Innovation

Rising innovation in reagents creates significant opportunities for suppliers of phosphoramidites, activators, solid supports, and high-purity solvents. Given the average process mass intensity of nearly 4,300 kg per kilogram of product highlighted by the American Chemical Society Green Chemistry Institute Pharmaceutical Roundtable, manufacturers are increasingly exploring solvent recycling, liquid-phase synthesis, enzymatic ligation, and continuous processing to reduce waste and costs.

Suppliers with GMP-grade, low-impurity reagents, such as Merck KGaA, Thermo Fisher Scientific Inc., and Agilent Technologies, Inc., are positioned to secure multi-year supply contracts as therapeutic programs advance toward commercialization. Vendors offering sustainable, scalable chemistries and robust regulatory documentation gain differentiation from commodity suppliers and opportunities to capture premium pricing as developers prioritize supply security and consistent quality.

Therapeutics Outsourcing, Chronic Disease Programs, and Individualized Medicines

Therapeutics is the fastest-growing application segment, creating opportunities in contract development and manufacturing. Pipelines are moving beyond rare diseases into common conditions: the WHO reports about 17.9 million annual deaths from cardiovascular disease, and oligonucleotides targeting lipoprotein(a) and PCSK9 are in advanced development or already on the market. The FDA has also issued draft guidance on individualized antisense oligonucleotide products, following the 2018 development of milasen, a custom therapy for a single child with Batten disease.

Outsourcing is increasing, benefiting WuXi AppTec Co., Ltd., ST Pharm Co., Ltd., Lonza Group AG, Bachem Holding AG, and GenScript Biotech Corporation, which offer integrated services ranging from sequence design to fill-finish. Providers that reserve capacity, offer rapid turnaround, and support small-batch, patient-specific production are positioned to capture high-value demand.

Category-Wise Analysis

Product Insights

Synthesized oligonucleotides dominate the product category, accounting for an estimated 42% market share in 2026. Their leading position is attributed to recurring demand from diagnostic, research, and therapeutic applications, where sequence-specific products are regularly procured for various workflows. Custom primers, probes, guide RNAs, and gene fragments generate consistent order volumes across academic institutions, diagnostic laboratories, pharmaceutical companies, and biotechnology firms.

Suppliers such as Integrated DNA Technologies, part of Danaher Corporation, GenScript Biotech Corporation, Eurofins Scientific SE, and Microsynth AG compete based on turnaround time, product quality, sequence accuracy, and customization capabilities. At the therapeutic level, around 20 FDA-approved oligonucleotide drugs generate demand for specialized active pharmaceutical ingredients (APIs) and commercial-scale manufacturing services. Research funding from the National Institutes of Health (NIH) and Horizon Europe further supports academic procurement, while high-throughput silicon-based synthesis technologies from Twist Bioscience Corporation are expanding manufacturing capacity.

Reagents are the fastest-growing product segment, registering an estimated CAGR of 10.6% through 2033. Segment growth is driven by increasing consumption of phosphoramidites, activators, solid supports, capping agents, and purification chemicals across research and commercial manufacturing applications. The expansion of therapeutic oligonucleotide pipelines and GMP manufacturing capacity is increasing procurement of high-purity reagents with consistent quality, validated specifications, and stringent impurity controls.

Furthermore, rising investments in sustainable synthesis technologies, solvent recovery, and advanced coupling chemistries are creating additional revenue opportunities for reagent manufacturers.

Application Insights

Research is the leading application segment, accounting for an estimated 36% market share in 2026. Its dominant position is supported by widespread utilization of synthetic oligonucleotides across academic research, molecular diagnostics development, genomics, and gene-editing studies. Academic and industrial laboratories routinely procure oligonucleotides for PCR and qPCR primers, sequencing adapters, CRISPR guide RNAs, siRNA research tools, and molecular probes, generating consistent demand across research workflows.

The National Institutes of Health (NIH) invests roughly US$ 47 billion annually in biomedical research, while Horizon Europe has a budget of about EUR 95.5 billion for 2021-2027.

Advances such as the FDA approval of Casgevy in December 2023 demonstrate the commercial translation of nucleic acid research, supporting continued investment in related technologies. Declining per-base synthesis costs and shorter delivery timelines from suppliers such as Integrated DNA Technologies, LGC Biosearch Technologies, and Thermo Fisher Scientific Inc. further support routine procurement across research institutions and biotechnology companies.

Therapeutics is the fastest-growing application segment, registering an estimated CAGR of 12.5% through 2033. Growth is driven by the expanding pipeline of antisense oligonucleotides (ASOs), small interfering RNA (siRNA), and other nucleic acid-based therapeutics targeting rare genetic disorders, cardiovascular diseases, neurological conditions, and metabolic disorders. Increasing commercial adoption of approved oligonucleotide medicines is generating demand for therapeutic-grade synthesis, active pharmaceutical ingredients (APIs), and specialized contract manufacturing services.

End-User Insights

Pharmaceutical companies represent the leading end-user segment, accounting for an estimated 34% market share in 2026. Their leading position is supported by substantial R&D expenditure, extensive drug development pipelines, and recurring procurement requirements for oligonucleotide active pharmaceutical ingredients (APIs) and research-grade materials. These companies utilize synthetic oligonucleotides across target discovery, preclinical research, clinical development, and commercial manufacturing.

PhRMA member companies invested about US$ 102 billion in research and development in 2023, highlighting the substantial investment base supporting demand for advanced drug development technologies.

Companies such as Novartis, which markets Leqvio, and Sanofi, which markets Qfitlia, have expanded their presence in the therapeutic oligonucleotide market alongside specialized developers such as Alnylam Pharmaceuticals and Ionis Pharmaceuticals. Commercial production requires multi-kilogram batches manufactured under GMP conditions, encouraging long-term procurement agreements with suppliers such as Agilent Technologies, Inc., Bachem Holding AG, Lonza Group AG, and WuXi AppTec Co., Ltd.

Biotechnology companies are the fastest-growing end-user segment, registering an estimated CAGR of 11.0% through 2033. Segment growth is supported by increasing venture capital investments, expanding nucleic acid therapeutic pipelines, and rising participation of biotechnology start-ups in antisense and siRNA drug development.

oligonucleotide-synthesis-market-outlook-by-product-2026-2033

Not every business fits the same mold. Your research shouldn't either.

Connect with the team for a customization and get a one-of-a-kind report scoped to your niche — The insights your competitors won't have access to.

Regional Analysis

North America Oligonucleotide Synthesis Market Trends and Insights

North America is the leading region, accounting for an estimated 37% share of the market in 2026. The region benefits from the presence of a large cluster of oligonucleotide drug developers, leading custom synthesis suppliers, and a supportive regulatory environment. The FDA reviews oligonucleotide drugs as new drug applications through its Center for Drug Evaluation and Research (CDER), providing a defined regulatory approval pathway.

Key market trends include the expansion of domestic GMP manufacturing capacity at Agilent Technologies, Inc. in Colorado, Integrated DNA Technologies in Iowa, and TriLink BioTechnologies in California, increasing outsourcing of synthesis activities, and efforts to diversify supply chains amid discussions surrounding the proposed BIOSECURE Act in the U.S. Congress. Canada further contributes to regional demand through its established academic research base and expanding biotechnology sector, while strong venture capital funding supports early-stage development programs that generate demand for synthesis services.

U.S. Oligonucleotide Synthesis Market Size

The U.S. oligonucleotide synthesis market is estimated at US$ 1.6 billion in 2026, representing roughly 90% of the North American market revenue. The National Institutes of Health (NIH) invests about US$ 47 billion annually in research, while the FDA has approved about 20 oligonucleotide drugs, many developed by U.S.-based companies such as Alnylam Pharmaceuticals in Cambridge and Ionis Pharmaceuticals in Carlsbad. Domestic suppliers, including Integrated DNA Technologies, Twist Bioscience Corporation, and Maravai LifeSciences Holdings, Inc., serve research, diagnostic, and therapeutic customers.

Increasing investments in chronic disease drug development, expanding adoption of molecular diagnostics, and efforts to strengthen domestic pharmaceutical supply chains represent key growth opportunities over the forecast period. Cell and gene therapy developers, academic medical centers, and diagnostic laboratories form a broad customer base, while collaboration among hospitals, universities, and startups in clusters such as Boston and San Diego accelerates the commercialization of new nucleic acid products.

Europe Oligonucleotide Synthesis Market Trends and Insights

Europe is projected to hold about 28% share of the global market in 2026, supported by leading oligonucleotide manufacturers, strong pharmaceutical R&D expenditure, and coordinated public research funding. Horizon Europe, with a budget of about EUR 95.5 billion for 2021-2027, supports genomics and advanced therapy research, while the European Medicines Agency (EMA) provides a defined regulatory approval pathway for oligonucleotide medicines. Regional industry participants include Bachem Holding AG and Lonza Group AG in Switzerland, Eurogentec, part of Kaneka Corporation, in Belgium, and Merck KGaA in Germany.

Key market trends include capacity expansion for GMP-grade oligonucleotide active pharmaceutical ingredients, investments in sustainable synthesis technologies, increasing demand for diagnostic and sequencing reagents, and strategic partnerships between pharmaceutical companies and contract manufacturers. Europe's stringent quality and regulatory requirements favor established suppliers with strong compliance records and long-standing customer relationships.

Germany Oligonucleotide Synthesis Market Size

Germany accounts for roughly 22% of the European market revenue. Merck KGaA, headquartered in Darmstadt, reported group sales of about EUR 21.2 billion in 2024 and supplies reagents and raw materials used in oligonucleotide production. Eurofins Genomics in Ebersberg is a major custom synthesis provider, while BioNTech in Mainz has strengthened its nucleic acid expertise.

Strong funding from the German Research Foundation (DFG), an established diagnostics industry, and demand from pharmaceutical manufacturers create opportunities for primers, probes, and therapeutic active ingredients across research and clinical applications. Collaboration between universities and industry accelerates technology commercialization, while increasing demand from contract testing laboratories supports recurring consumption of reagents, consumables, and custom oligonucleotides across the country.

U.K. Oligonucleotide Synthesis Market Size

The U.K. is expected to hold roughly 20% share of the European market in 2026. LGC Biosearch Technologies, part of the Teddington-based LGC group, supplies probes and custom oligonucleotides to diagnostic and research customers. Genomics England sequenced 100,000 genomes, while UK Biobank maintains data on about 500,000 participants, supporting demand for sequencing reagents and targeted genomic panels.

Academic centers in Oxford and London are active in oligonucleotide therapy research for neuromuscular diseases, while the Medicines and Healthcare products Regulatory Agency (MHRA) supports access to innovative medicines, creating opportunities for therapeutic oligonucleotide synthesis. Strong academic research output, active startup formation, and funding from national research councils sustain demand for oligonucleotides, while access to global pharmaceutical customers supports the commercialization of domestic technologies.

France Oligonucleotide Synthesis Market Size

France accounts for an estimated 13% of European market revenue. Sanofi, which markets Qfitlia, and research centers such as the Institut Pasteur and Inserm contribute to demand for research and therapeutic oligonucleotides. The Genopole biocluster in Evry hosts genomics and gene therapy companies, while Eurofins Scientific SE, which originated in Nantes in 1987, operates extensive genomic and diagnostic testing services. The France 2030 investment plan allocates about €7.5 billion to health innovation, creating opportunities for domestic manufacturing of biotherapies and nucleic acid medicines.

Public hospital networks and national funding for biotherapies further support translational research, while collaboration with pharmaceutical and diagnostic companies sustains recurring demand for synthetic nucleic acids. Growing partnerships with global drug developers further strengthen the country's market position.

Asia Pacific Oligonucleotide Synthesis Market Trends and Insights

Asia Pacific represents the fastest-growing regional market, growing at an estimated CAGR of 11.0% during 2026 - 2033. China is a key contributor to regional market growth, as the National Medical Products Administration (NMPA) joined the International Council for Harmonisation (ICH) in 2017, while domestic companies such as GenScript Biotech Corporation and WuXi AppTec Co., Ltd. have established substantial synthesis and contract manufacturing capacities. South Korea contributes through ST Pharm Co., Ltd., a leading oligonucleotide manufacturer, while Japan adds strength through its advanced pharmaceutical R&D ecosystem.

Key regional trends include increasing outsourcing by Western pharmaceutical sponsors seeking cost-competitive manufacturing capacity, expanding molecular diagnostics, growing genomic research initiatives, and government support for biotechnology development. Geopolitical concerns surrounding pharmaceutical supply chains are likely to influence sourcing strategies, while established manufacturing infrastructure and scientific talent position Asia Pacific as a key growth market for oligonucleotide synthesis suppliers.

India Oligonucleotide Synthesis Market Size

India is estimated to hold roughly 7% share of the Asia Pacific market in 2026. The BioE3 Policy, approved in August 2024, promotes domestic biomanufacturing, while the Department of Biotechnology and the Indian Council of Medical Research (ICMR) fund genomics and diagnostics research. An estimated 70 million people live with rare diseases in India, according to commonly cited estimates, supporting interest in nucleic acid-based therapies, while the expanding molecular diagnostics sector generates demand for synthetic primers and probes.

Domestic custom synthesis providers and regional laboratories of global companies are expanding manufacturing and service capabilities to serve universities and diagnostic companies. Government-backed incubators and a growing pool of trained life science graduates are expected to support domestic market demand over the forecast period, particularly among universities, diagnostic chains, and mid-sized biotechnology companies.

Japan Oligonucleotide Synthesis Market Size

Japan is expected to hold around 17% share of the Asia Pacific market in 2026. Nippon Shinyaku Co., Ltd. developed Viltepso, an antisense drug approved in 2020, while companies such as Daiichi Sankyo and Takeda maintain active nucleic acid development programs. Kaneka Corporation, owner of Eurogentec, and Nitto Denko Corporation, parent of Nitto Avecia, contribute to the country's oligonucleotide synthesis capabilities.

With about 29% of the population aged 65 or older, according to the Ministry of Internal Affairs and Communications, demand for therapies targeting chronic and neuromuscular diseases is increasing, while the Japan Agency for Medical Research and Development (AMED) supports translational research. Strong domestic instrument and chemical manufacturing capabilities, together with government funding, support commercialization and sustained adoption of oligonucleotides across research and therapeutic applications. Increasing private-sector investment further strengthens the market outlook.

oligonucleotide-synthesis-market-outlook-by-region-2026-2033

Competitive Landscape

The global oligonucleotide synthesis market is moderately consolidated, with diversified life science companies competing alongside specialized synthesis providers and contract manufacturing organizations. Thermo Fisher Scientific Inc. reported revenue of about US$ 42.9 billion in 2024, while Danaher Corporation, the parent company of Integrated DNA Technologies, reported revenue of about US$ 23.9 billion, providing both companies with substantial scale across custom oligonucleotides, reagents, and instruments.

Agilent Technologies, Inc., Bachem Holding AG, Lonza Group AG, WuXi AppTec Co., Ltd., and ST Pharm Co., Ltd. differentiate themselves through GMP manufacturing capabilities for therapeutic active ingredients, while Twist Bioscience Corporation leverages silicon-based synthesis technology to support high-throughput DNA production.

Key competitive strategies include manufacturing capacity expansion, process automation, investments in sustainable synthesis chemistry, and strengthening of quality management systems. Emerging business models include capacity reservation agreements, integrated service offerings covering sequence design through fill-finish, and long-term supply partnerships with pharmaceutical and biotechnology companies. Suppliers with scalable manufacturing infrastructure, consistent product quality, regulatory compliance capabilities, and integrated service portfolios are positioned to strengthen their competitive presence and capture a larger share of the expanding market.

Key Industry Developments

  • In March 2025, the U.S. Food and Drug Administration approved Qfitlia (fitusiran), an siRNA therapy from Sanofi developed with Alnylam Pharmaceuticals, for hemophilia A and B, adding another commercial-scale oligonucleotide product that requires GMP-grade synthesis capacity from manufacturers and reagent suppliers. The approval follows the FDA clearance of earlier siRNA drugs.
  • In December 2024, the FDA approved Tryngolza (olezarsen), an antisense therapy from Ionis Pharmaceuticals, for familial chylomicronemia syndrome, extending the oligonucleotide drug class into cardiometabolic disease and supporting demand for large-scale active ingredient supply. The approval also reflects growing commercial interest in antisense medicines.

Companies Covered in Oligonucleotide Synthesis Market

  • Thermo Fisher Scientific Inc.
  • Danaher Corporation (Integrated DNA Technologies)
  • Merck KGaA
  • Agilent Technologies, Inc.
  • Eurofins Scientific SE
  • LGC Biosearch Technologies
  • GenScript Biotech Corporation
  • Maravai LifeSciences Holdings, Inc. (TriLink BioTechnologies)
  • Kaneka Corporation (Eurogentec)
  • Twist Bioscience Corporation
  • Bachem Holding AG
  • Lonza Group AG
  • WuXi AppTec Co., Ltd.
  • ST Pharm Co., Ltd.
Frequently Asked Questions

The global oligonucleotide synthesis market size is estimated at US$ 5.4 billion in 2026 and is projected to reach US$ 10.0 billion by 2033, expanding at a CAGR of 9.2% between 2026 and 2033.

The market is driven by the growing number of approved oligonucleotide drugs, increasing demand for molecular diagnostics, and rising investments in genomics research.

North America is likely to lead the market with an estimated 37% share in 2026, supported by NIH funding, a cluster of drug developers, and the presence of established suppliers such as Integrated DNA Technologies.

The key opportunities lie in innovation in reagents and therapeutics. Greener chemistries, outsourced manufacturing and individualized antisense medicines offer additional revenue pockets for suppliers and contract manufacturers. Suppliers that combine GMP-grade quality, sustainable processes, and rapid turnaround are best placed to capture this demand and secure multi-year supply agreements.

Leading companies include Thermo Fisher Scientific Inc., Danaher Corporation (Integrated DNA Technologies), Merck KGaA, Agilent Technologies, Inc., Eurofins Scientific SE, LGC Biosearch Technologies, GenScript Biotech Corporation, Maravai LifeSciences Holdings, Inc., Kaneka Corporation, Twist Bioscience Corporation, Bachem Holding AG, Lonza Group AG, WuXi AppTec Co., Ltd., and ST Pharm Co., Ltd.

UK

Corporate Office

Persistence Research & Consultancy Services Limited

Company Number : 15310893

Second Floor, 150 Fleet Street,London, EC4A 2DQ.

+44 203-837-5656
USA

Regional Office

Persistence Market Research

108 W 39th Street, Ste 1006,PMB2219, New York, NY 10018

+1 646-878-6329
India

Global Research centre

Persistence Market Research Private Limited

CIN : U74900PN2014PTC153163

6th Floor, Teerth Technospace, Teerth Realties, Office No. B- 604, Baner, Pune, Maharashtra 411045

Copyright © 2026 Persistence Market Research. All Rights Reserved

Connect With Us -